pyrazinamide
E928064
World Health Organization essential medicine
antitubercular drug
first-line antitubercular agent
nicotinamide analog
pharmaceutical drug
prodrug
Pyrazinamide is a first-line antitubercular drug used in combination therapy to shorten and intensify treatment of tuberculosis caused by the Mycobacterium tuberculosis complex.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Pyrazinamide | 0 |
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
World Health Organization essential medicine
ⓘ
antitubercular drug ⓘ first-line antitubercular agent ⓘ nicotinamide analog ⓘ pharmaceutical drug ⓘ prodrug ⓘ |
| activatedBy | mycobacterial pyrazinamidase ⓘ |
| activeAgainst | semi-dormant mycobacteria in acidic environments ⓘ |
| belongsToClass | antimycobacterial agents ⓘ |
| contraindicatedIn |
acute gout
ⓘ
severe hepatic impairment ⓘ |
| contributesTo | shortening duration of tuberculosis therapy ⓘ |
| discoveredIn | 1950s ⓘ |
| eliminatedVia | kidney ⓘ |
| hasAdverseEffect |
arthralgia
ⓘ
gastrointestinal upset ⓘ hepatotoxicity ⓘ hyperuricemia ⓘ |
| hasATCCode | J04AK01 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasCASNumber | 98-96-4 ⓘ |
| hasChemicalFormula | C5H5N3O ⓘ |
| hasDefinedDailyDose | 1.5 g (oral, adult) ⓘ |
| hasIUPACName | pyrazine-2-carboxamide ⓘ |
| hasLegalStatus | prescription-only medicine ⓘ |
| hasMechanismOfAction | disrupts membrane transport and energy production in Mycobacterium tuberculosis ⓘ |
| hasMeltingPoint | ~190 °C ⓘ |
| hasMolarMass | 123.11 g/mol ⓘ |
| hasPregnancyCategoryUS | C ⓘ |
| hasProteinBinding | low ⓘ |
| hasRouteOfAdministration |
intravenous
ⓘ
oral ⓘ |
| hasTargetOrganism |
Mycobacterium bovis (some strains resistant)
ⓘ
Mycobacterium tuberculosis NERFINISHED ⓘ |
| hasTypicalDoseRange | 20–30 mg/kg/day ⓘ |
| includedIn | WHO Model List of Essential Medicines NERFINISHED ⓘ |
| isOn | World Health Organization List of Essential Medicines NERFINISHED ⓘ |
| isProdrugOf | pyrazinoic acid ⓘ |
| metabolizedIn | liver ⓘ |
| usedDuring | intensive phase of tuberculosis treatment ⓘ |
| usedFor |
drug-susceptible pulmonary tuberculosis
ⓘ
tuberculosis ⓘ tuberculosis caused by Mycobacterium tuberculosis complex ⓘ |
| usedInCombinationWith |
ethambutol
NERFINISHED
ⓘ
isoniazid ⓘ rifampicin NERFINISHED ⓘ streptomycin NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.